Vera Therapeutics, Inc. (VERA)
Vera Therapeutics develops drug candidates for serious immune system diseases, led by atacicept for IgA nephropathy, a kidney disease. It last closed at $26.20 on Nov 17, down 2.86% on the day. The average 12-month price target from 5 analysts is $57.40 (+119.1% from the last close), with a high of $83.00 and a low of $29.00. Analyst consensus is Buy, based on the latest ratings from 5 firms (3 buy, 2 hold, 0 sell). Over the past 90 days StreetAlpha recorded 4 whale options trades in VERA, 75% of them bullish and 25% bearish.
Key Stats
Last 12 monthsNot reported for this period.
From VERA's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 5). Last 12 months adds up the four latest quarters.
Earnings
Full earnings history →Analyst Ratings & Price Targets
Analyst Ratings →Based on 5 analysts who set a price target on VERA in the past 90 days. The average target is $57.40, with a high of $83.00 and a low of $29.00, compared with the last close of $26.20.
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| Nov 6 | Wedbush | Target lowered | Hold | $34 → $29 |
| Nov 6 | Guggenheim | Target lowered | Buy | $76 → $66 |
| Nov 6 | HC Wainwright & Co. | Target lowered | Buy | $90 → $75 |
| Oct 12 | Leerink Partners | Initiated | Hold | $34 |
| Sep 8 | JP Morgan | Maintained | Buy | $83 |
Technical Analysis
The stock is 13% below its 20 day and 17% below its 50 day average. It is 37% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 36), near oversold. The nearest support is the 52 week low at $25.82, and the nearest resistance the Pivot at $26.32.
| RSI (14) | 35.58 | Weak, oversold below 30 | Neutral |
| MACD | -0.73 | Below its signal line | Bearish |
| Stochastic | 4.2 | Near the bottom of its range | Oversold |
| ADX (14) | 13.9 | No clear trend | |
| Williams %R | -94.5 | Oversold below −80, overbought above −20 | Oversold |
| CCI (20) | -206.2 | Oversold below −100, overbought above 100 | Oversold |
| Rate of change | −14.7% | Change over 10 sessions | Bearish |
| ATR (14) | $1.61 | Typical daily range, 6.2% of price |
| RSI (14) | 35.95 | Weak, oversold below 30 | Neutral |
| MACD | -2.42 | Below its signal line | Bearish |
| Stochastic | 17.0 | Near the bottom of its range | Oversold |
| ADX (14) | 14.4 | No clear trend | |
| Williams %R | -96.6 | Oversold below −80, overbought above −20 | Oversold |
| CCI (20) | -132.4 | Oversold below −100, overbought above 100 | Oversold |
| Rate of change | −25.3% | Change over 10 sessions | Bearish |
| ATR (14) | $4.16 | Typical daily range, 15.9% of price |
What happened before
See how VERA did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
Seasonality
How VERA has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2021.
Whale Options Flow
90DNo whale options trades in VERA in the last 90 days.
VERA Institutional Ownership
Full report →- ▲128 buying vs 96 selling
- ▲Held by funds +9.6 pts
- ▲Funds holding +3
- ▼Superinvestors: 1 added, 2 cut
- ●Put/call not meaningful
| Q3 2026 | This quarter | Last quarter | Change |
|---|---|---|---|
| Funds holding | 224 | 221 | +1.4% |
| In funds' top 10 | 13 | 7 | +85.7% |
| Held by funds | 117.4% | 107.8% | +9.6 pts |
| New / increased | 39 / 89 | 28 / 98 | +1.6% |
| Reduced / sold out | 59 / 37 | 66 / 37 | −6.8% |
| Put/call ratio | 3.38 | 0.55 | +517.8% |
From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.
AI Auto Pilots
Paper tradingStreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether VERA is in one of them and how their past VERA trades turned out.
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered VERA in an article yet. Here's the latest on the wider market.
About Vera Therapeutics
Vera Therapeutics is a biotechnology company based in Brisbane, California, that develops treatments for serious immune system diseases, with a focus on kidney conditions. Its lead candidate, atacicept, is being studied for IgA nephropathy, a kidney disease, and other autoimmune kidney disorders, and is designed to be given at home by autoinjector. The company also holds rights to MAU868, which is being studied for BK viremia in kidney transplant patients, and to VT109, a preclinical candidate. Its target customers are patients with these conditions and the doctors who treat them.
- Headquarters
- Brisbane, CA


